Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1954 1
1957 1
1960 2
1964 1
1971 1
1973 3
1977 1
1978 1
1980 1
1981 2
1982 3
1983 3
1984 1
1985 8
1986 10
1987 23
1988 24
1989 42
1990 37
1991 47
1992 58
1993 53
1994 58
1995 80
1996 88
1997 94
1998 89
1999 108
2000 112
2001 99
2002 139
2003 125
2004 86
2005 92
2006 96
2007 90
2008 80
2009 77
2010 73
2011 59
2012 75
2013 53
2014 77
2015 76
2016 56
2017 55
2018 56
2019 63
2020 44
2021 52
2022 45
2023 54
2024 45
2025 74
2026 38

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,654 results

Results by year

Filters applied: . Clear all
Page 1
Tailoring transdermal estradiol dose to maximize benefits and minimize risks.
Glynne SJ, Simon JA. Glynne SJ, et al. Menopause. 2026 Jun 1;33(6):743-753. doi: 10.1097/GME.0000000000002723. Menopause. 2026. PMID: 41529140
Transdermal estradiol is licensed to treat estradiol deficiency symptoms and prevent osteoporosis in postmenopausal women. ...An understanding of transdermal estradiol pharmacokinetics and pharmacodynamics, and the limitations of the methods use …
Transdermal estradiol is licensed to treat estradiol deficiency symptoms and prevent osteoporosis in postmenopausal wom …
Transdermal estradiol for the management of refractory uremic bleeding.
Gonzalez J, Bryant S, Hermes-DeSantis ER. Gonzalez J, et al. Am J Health Syst Pharm. 2018 May 1;75(9):e177-e183. doi: 10.2146/ajhp170241. Am J Health Syst Pharm. 2018. PMID: 29691259 Review.
PURPOSE: The efficacy and thrombogenicity of transdermal estradiol in the management of refractory uremic bleeding in adults are examined. ...In this clinical scenario, a weak conditional recommendation (grade 2C) supporting transdermal estradiol as a …
PURPOSE: The efficacy and thrombogenicity of transdermal estradiol in the management of refractory uremic bleeding in adults a …
17 beta-estradiol/levonorgestrel transdermal system.
Dando TM, Perry CM. Dando TM, et al. Treat Endocrinol. 2004;3(5):319-24. doi: 10.2165/00024677-200403050-00005. Treat Endocrinol. 2004. PMID: 15330679 Review.
Hormone replacement therapy with continuous 17 beta-estradiol/levonorgestrel (estradiol/levonorgestrel), administered once weekly as a transdermal system, has shown efficacy in the treatment of vasomotor symptoms associated with menopause. ...The estradiol …
Hormone replacement therapy with continuous 17 beta-estradiol/levonorgestrel (estradiol/levonorgestrel), administered once wee …
Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.
Wiseman LR, McTavish D. Wiseman LR, et al. Drugs Aging. 1994 Mar;4(3):238-56. doi: 10.2165/00002512-199404030-00006. Drugs Aging. 1994. PMID: 8199397 Review.
The combined transdermal estradiol/norethisterone therapeutic system is designed to deliver both estradiol and norethisterone into the systemic circulation at a constant rate for up to 4 days when affixed to the skin. ...Menopausal symptoms are improved to a …
The combined transdermal estradiol/norethisterone therapeutic system is designed to deliver both estradiol and norethis …
Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints.
Balfour JA, Heel RC. Balfour JA, et al. Drugs. 1990 Oct;40(4):561-82. doi: 10.2165/00003495-199040040-00006. Drugs. 1990. PMID: 2083514 Review.
The estradiol transdermal therapeutic system is a cutaneous delivery device which delivers estradiol into the systemic circulation via the stratum corneum at a constant rate for up to 4 days. ...As with oral or injectable estrogen replacement therapy, …
The estradiol transdermal therapeutic system is a cutaneous delivery device which delivers estradiol into the sy …
Transdermal estradiol.
Basdevant A, Conard J, Guy-Grand B. Basdevant A, et al. N Engl J Med. 1986 Dec 11;315(24):1550-1. doi: 10.1056/NEJM198612113152414. N Engl J Med. 1986. PMID: 3785313 No abstract available.
Transdermal estradiol and testosterone transfer in man: existence, models, and strategies for prevention.
Busse KL, Maibach HI. Busse KL, et al. Skin Pharmacol Physiol. 2011;24(2):57-66. doi: 10.1159/000321444. Epub 2010 Nov 18. Skin Pharmacol Physiol. 2011. PMID: 21088452 Review.
We used the following key words: transfer, transdermal, absorption, cutaneous, hormone, estradiol, and testosterone. Unpublished trials were reviewed on the US Food and Drug Administration (FDA) website for product approval. RESULTS: Data reflecting in …
We used the following key words: transfer, transdermal, absorption, cutaneous, hormone, estradiol, and testosterone. Un …
Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis.
Balfour JA, McTavish D. Balfour JA, et al. Drugs Aging. 1992 Nov-Dec;2(6):487-507. doi: 10.2165/00002512-199202060-00005. Drugs Aging. 1992. PMID: 1493353 Review.
The estradiol transdermal therapeutic system is a percutaneous delivery device which, when affixed to the skin, delivers estradiol (the major estrogen in premenopausal women) into the systemic circulation at a constant rate for up to 4 days. ...The tolerabili …
The estradiol transdermal therapeutic system is a percutaneous delivery device which, when affixed to the skin, delivers es …
Transdermal Delivery of Estradiol Simultaneously Possessing Rapid Release and Sustained Release Effect.
Tang X, Qin H, Yang J, Zhang X. Tang X, et al. AAPS PharmSciTech. 2023 Jun 23;24(6):145. doi: 10.1208/s12249-023-02604-w. AAPS PharmSciTech. 2023. PMID: 37353673
The aim of this study was to design a novel DMN system for the administration of the poorly water-soluble drug, estradiol (E2), with fast skin penetration and a stable release rate for a long time. ...In summary, the E2-EM-DMN showed reliable quality and superior re …
The aim of this study was to design a novel DMN system for the administration of the poorly water-soluble drug, estradiol (E2) …
Choice of progestogen for endometrial protection in combination with transdermal estradiol in menopausal women.
Mueck AO, Römer T. Mueck AO, et al. Horm Mol Biol Clin Investig. 2018 Jul 31;37(2). doi: 10.1515/hmbci-2018-0033. Horm Mol Biol Clin Investig. 2018. PMID: 30063464 Review.
Transdermal estradiol (TE) application (using gels, patches or a novel spray) is now a preferred route of hormone therapy (HT) in menopausal women, because various risks such as venous thromboembolism, stroke and unwanted hepatic effects can be reduced compared with …
Transdermal estradiol (TE) application (using gels, patches or a novel spray) is now a preferred route of hormone therapy (HT) …
2,654 results